Robin L. Jones, BSc, MB BS, MRCP, MD

Professor
Sarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, United Kingdom

Robin Jones is a medical oncologist specialising in the treatment of sarcomas and Head of the Sarcoma Unit at The Royal Marsden. He has experience in conducting Phase I, II and III trials, as well translational studies in sarcomas. Professor Jones trained in medical oncology at The Royal Marsden and between 2010 and 2014 he was Head of the Sarcoma Program at the University of Washington/Fred Hutchinson Cancer Research Center in Seattle. His main research interest focuses on clinical trials and translational research in sarcomas.

Poster(s):

• (P 23) METASTATIC ALVEOLAR SOFT PART SARCOMA: PREGNANCY-RELATED WORSENING AND SPONTANEOUS EXCEPTIONAL REMISSION POSTPARTUM- A CASE REPORT.

• (P 87) SAFETY AND EFFICACY OF OLUTASIDENIB, AN IDH1 MUTANT INHIBITOR, FOR THE TREATMENT OF RECURRENT/ RELAPSED LOCALLY ADVANCED OR METASTATIC IDH1 MUTATED CHONDROSARCOMA

• (P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE

• (P 183) A RETROSPECTIVE STUDY OF THE EFFECTS OF PATIENT, DISEASE, AND TREATMENT FACTORS ON SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA BRAIN METASTASES

• (P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS

• (P 401) A PHASE 3 MULTI-CENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF EMACTUZUMAB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR (TANGENT)

• (P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.